KEYTRUDA (pembrolizumab) received FDA approval for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
